Targeting Janus kinases in the treatment of autoimmune disease

Key Takeaways for GI Nurses

• Janus kinase (JAK) inhibitors are an increasingly important class of medications used to treat several autoimmune conditions seen in GI practice, most notably inflammatory bowel disease (IBD), and GI nurses should be familiar with their mechanism of action and monitoring requirements.
• JAK3 signaling is essential for multiple cytokine pathways (IL-2, IL-4, IL-7, IL-9, IL-15, IL-21) that drive immune and inflammatory responses—understanding this helps explain why JAK inhibitors can broadly suppress inflammation in conditions like ulcerative colitis and Crohn's disease.
• Patients on JAK inhibitor therapy require careful pre-procedure assessment and peri-endoscopic management, as these medications affect immune function and may influence bleeding risk, infection risk, and healing after biopsy or polypectomy.
• As more patients present for endoscopy with a history of JAK-targeted therapy for IBD or other autoimmune diseases, nurses play a key role in medication reconciliation, patient education, and recognizing signs of drug-related complications such as infection or cytokine-related adverse events.

Clinical Relevance

This research summary highlights the foundational science behind JAK3 inhibition, a mechanism now central to the treatment of IBD and other immune-mediated diseases encountered in gastroenterology practice. JAK inhibitors such as tofacitinib and upadacitinib are approved for ulcerative colitis and are used off-label or in trials for Crohn's disease, reflecting the clinical translation of this cytokine-pathway research. For endoscopy nurses, this means an expanding population of patients who are immunomodulated through a different mechanism than traditional biologics (anti-TNF, anti-integrin, anti-IL-12/23 agents), requiring updated knowledge for safe periprocedural care.

From a practical standpoint, nurses conducting pre-procedure assessments should ask specifically about JAK inhibitor use, as these oral small-molecule agents are easy to overlook compared to injectable biologics. Because JAK inhibitors affect multiple cytokine pathways involved in lymphocyte development and immune surveillance, patients may have altered susceptibility to infection, herpes zoster reactivation, or delayed mucosal healing—factors relevant when performing biopsies, polypectomies, or dilations. Nurses should also be alert to black-box warnings associated with this drug class, including risks of thrombosis, malignancy, and major adverse cardiovascular events, and incorporate appropriate screening questions into pre-procedure intake.

On a professional development level, this research underscores the value of nurses staying current on the pharmacology of emerging IBD therapies. As GI units increasingly manage patients with complex autoimmune comorbidities—sometimes overlapping conditions such as psoriatic arthritis, ankylosing spondylitis, or atopic dermatitis alongside IBD—nurses benefit from understanding shared cytokine pathways and why a single drug class may be prescribed across multiple specialties. This knowledge supports better interdisciplinary communication with rheumatology and dermatology colleagues co-managing these patients, and strengthens patient education about why their "arthritis drug" or "psoriasis drug" is also used for their bowel disease.

Bottom Line

JAK inhibitors, grounded in foundational research on JAK3 and cytokine signaling, are an important and growing drug class for IBD and other autoimmune diseases; GI nurses should ensure these oral medications are captured during medication reconciliation and factored into periprocedural risk assessment, given their immunomodulatory effects and associated safety warnings.